These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

821 related items for PubMed ID: 20564403

  • 1. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK.
    Cancer; 2010 Jun 15; 116(12):2974-83. PubMed ID: 20564403
    [Abstract] [Full Text] [Related]

  • 2. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.
    Hum Pathol; 2012 Oct 15; 43(10):1573-82. PubMed ID: 22417847
    [Abstract] [Full Text] [Related]

  • 3. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
    Zafon C, Obiols G.
    Endocrinol Nutr; 2009 Apr 15; 56(4):176-86. PubMed ID: 19627734
    [Abstract] [Full Text] [Related]

  • 4. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
    Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, De Micco C.
    Hum Pathol; 2006 Jul 15; 37(7):824-30. PubMed ID: 16784981
    [Abstract] [Full Text] [Related]

  • 5. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.
    Cancer Res; 2003 Aug 01; 63(15):4561-7. PubMed ID: 12907632
    [Abstract] [Full Text] [Related]

  • 6. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E.
    Clin Endocrinol (Oxf); 2006 Jan 01; 64(1):105-9. PubMed ID: 16402937
    [Abstract] [Full Text] [Related]

  • 7. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
    Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simões M.
    J Clin Endocrinol Metab; 2006 Jan 01; 91(1):213-20. PubMed ID: 16219715
    [Abstract] [Full Text] [Related]

  • 8. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV, Rumiantsev PO, Saenko VA, Il'in AA, Poliakova EIu, Nemtsova MV, Zaletaev DV.
    Mol Biol (Mosk); 2004 Jan 01; 38(4):642-53. PubMed ID: 15456136
    [Abstract] [Full Text] [Related]

  • 9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 10. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.
    Pathol Int; 2007 Jan 01; 57(1):12-20. PubMed ID: 17199737
    [Abstract] [Full Text] [Related]

  • 11. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M.
    J Clin Endocrinol Metab; 2008 Aug 01; 93(8):3106-16. PubMed ID: 18492751
    [Abstract] [Full Text] [Related]

  • 12. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M.
    Thyroid; 2010 Jul 01; 20(7):697-706. PubMed ID: 20578891
    [Abstract] [Full Text] [Related]

  • 13. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y.
    Thyroid; 2014 Aug 01; 24(8):1256-66. PubMed ID: 24798740
    [Abstract] [Full Text] [Related]

  • 14. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.
    Menges CW, McCance DJ.
    Oncogene; 2008 May 01; 27(20):2934-40. PubMed ID: 18059341
    [Abstract] [Full Text] [Related]

  • 15. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
    Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M.
    Oncogene; 2003 Jul 17; 22(29):4578-80. PubMed ID: 12881714
    [Abstract] [Full Text] [Related]

  • 16. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
    Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M, Imai K, Cologne J, Soda M, Arihiro K, Fujihara M, Abe K, Hayashi T, Nakashima M, Sekine I, Yasui W, Hayashi Y, Nakachi K.
    Cancer Res; 2008 Sep 01; 68(17):7176-82. PubMed ID: 18757433
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous occurrence of PAX8-PPARg and RET-PTC3 rearrangements in a follicular variant of papillary thyroid carcinoma.
    Caria P, Dettori T, Frau DV, Di Oto E, Morandi L, Parmeggiani A, Tallini G, Vanni R.
    Am J Surg Pathol; 2012 Sep 01; 36(9):1415-20. PubMed ID: 22895275
    [Abstract] [Full Text] [Related]

  • 18. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.
    Oncogene; 2000 Sep 28; 19(41):4685-94. PubMed ID: 11032018
    [Abstract] [Full Text] [Related]

  • 19. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS.
    J Clin Endocrinol Metab; 2008 Feb 15; 93(2):611-8. PubMed ID: 18000091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.